Fortress Biotech Inc. (FBIO) had a good day on the market for Tuesday November 12 as shares jumped 7.95% to close at $1.63. About 259,434 shares traded hands on 869 trades for the day, compared with an average daily volume of n/a shares out of a total float of 69.04 million. After opening the trading day at $1.50, shares of Fortress Biotech Inc. stayed within a range of $1.65 to $1.45.
With today’s gains, Fortress Biotech Inc. now has a market cap of $112.54 million. Shares of Fortress Biotech Inc. have been trading within a range of $2.59 and $0.49 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Fortress Biotech Inc. is based out of New York, NY and has some 88 employees. Its CEO is Lindsay A. Rosenwald.
Fortress Biotech Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
